


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) A compound of formula (I)



including salts, solvates, and pharmaceutically functional derivatives thereof, wherein

t is 0, 1, 2, 3, or 4;

R^1 is alkyl, alkoxy, halogen, haloalkyl, nitro, cyano, or $-NR^7R^8$, where each of R^7 and R^8 independently are H or alkyl;

A is $-OH$ or $-NR^2R^3$;

each of R^2 and R^3 independently is H or $-(Q^1)_n-R^4$;

n is 0, 1 or 2;

Q^1 is alkylene;

each R^4 independently is alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxy, alkoxy, or aryloxy;

X^1 is $-NH-$;

X^2 is $-C(R^5)_2-$;

each R^5 independently is H or alkyl;

Y is aryl or heteroaryl;

Z is $-(Q^2)_m-R^6$;

m is 0 or 1;

Q^2 is $-NR^5-$, $-O-$, $-S-$, $-O(CH_2)_p-$, or $-CH_2-$;

p is 1, 2, or 3; and

R⁶ is aryl or heteroaryl.

2. (Original) The compound of claim 1 wherein X² is –CH₂–.
3. (Original) The compound of claim 2 wherein X¹ is substituted *para* to the depicted cyclopropyl ring.
4. (Original) The compound of claim 1 wherein t is 0.
5. (Original) The compound of claim 1 wherein Y is aryl.
6. (Original) The compound of claim 5 wherein Y is phenyl.
7. (Original) The compound of claim 6 wherein said phenyl is unsubstituted or is optionally substituted with C₁–C₆ alkyl, C₁–C₆ alkoxy, halogen, or C₁–C₆ haloalkyl.
8. (Original) The compound of claim 1 wherein Y is heteroaryl.
9. (Original) The compound of claim 8 wherein Y is thiazolyl.
10. (Original) The compound of claim 9 wherein said thiazolyl is unsubstituted or is optionally substituted with C₁–C₆ alkyl, aryl, or heteroaryl.
11. (Original) The compound of claim 1 wherein A is –OH.
12. (Original) The compound of claim 11 wherein the compound of formula (I) is a pharmaceutically functional derivative.
13. (Original) The compound of claim 12 wherein A is –OR⁹ where R⁹ is alkyl or aryl.

14. (Original) The compound of claim 1 wherein Q^1 is unsubstituted alkylene.
15. (Original) The compound of claim 1 wherein Q^1 is optionally substituted alkylene.
16. (Original) The compound of claim 1 wherein Z is $-O-R^6$.
17. (Original) The compound of claim 16 wherein R^6 is phenyl.
18. (Original) The compound of claim 17 wherein said phenyl is unsubstituted or is optionally substituted with halogen, C_1-C_6 haloalkyl, or C_1-C_6 alkoxy.
19. (Original) The compound of claim 1 wherein Z is $-R^6$.
20. (Original) The compound of claim 19 wherein R^6 is phenyl.
21. (Original) The compound of claim 20 wherein said phenyl is unsubstituted or is optionally substituted with halogen, C_1-C_6 haloalkyl, or C_1-C_6 alkoxy.
22. (Original) The compound of claim 21 wherein R^6 is heteroaryl.
23. (Original) The compound of claim 1 wherein A is $-OH$, t is 0, X^1 is $-NH-$, X^2 is $-CH_2-$, Y is phenyl, m is 1, Q^2 is $-O-$, and R^6 is phenyl.
24. (Original) The compound of claim 1 wherein A is $-OH$, t is 0, X^1 is $-NH-$, X^2 is $-CH_2-$, Y is thiazolyl, m is 0, and R^6 is phenyl substituted with $-CF_3$.

25. (Original) The compound of claim 1 wherein the compound is selected from:

Racemic-(trans)-2-[4-([3-(phenyloxy)phenyl]methyl)ammonium)phenyl] cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-biphenyl)methyl]amino]phenyl}cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-([4-(2-pyridinyl)phenyl]methyl)amino)phenyl] cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(3,4-dichlorophenyl)oxy]phenyl)methyl]ammonium phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-(4-[(3-[[4-(methyloxy)phenyl]oxy}phenyl)methyl]ammonium phenyl)-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(4-chlorophenyl)oxy]phenyl)methyl]ammonium]phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-(4-[(3-[[4-(1,1-dimethylethyl)phenyl]oxy}phenyl)methyl] ammonium}phenyl)cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(3,5-dichlorophenyl)oxy]phenyl)methyl]ammonium phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-(4-[(3-[[3-(trifluoromethyl)phenyl]oxy}phenyl)methyl] ammonium}-phenyl)cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(4-methylphenyl)oxy]phenyl)methyl]ammonium]phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(3-[(phenylmethyl)oxy]phenyl)methyl]ammonium]phenyl}-cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-([4-methyl-2-(phenyloxy)-1,3-thiazol-5-yl]methyl)ammonium)-phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[5-(4-chlorophenyl)-2-furanyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[4-[(phenylmethyl)oxy]phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[2-[(3,4-difluorophenyl)oxy]-4-methyl-1,3-thiazol-5-yl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[5-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[4-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[3-(phenylmethyl)phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[3-[(4-nitrophenyl)oxy]phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[3-(phenylthio)phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Racemic-(trans)-2-[4-({[3-[(4-aminophenyl)oxy]phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

(-)-(Trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}amino)phenyl]cyclopropane carboxylic acid;

(+)-(Trans)-2-[4-[(3-phenoxybenzyl)amino]phenyl]cyclopropanecarboxylic acid;

(+)-(Trans)-2-[4-({[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Enantiomerically enriched (trans)-ethyl-2-[4-({[3-[(3,4-dichlorophenyl)oxy]phenyl] methyl}amino)phenyl]-cyclopropanecarboxylate;

(+)-(Trans)-2-[4-({[3-[(3,4-dichlorophenyl)oxy]phenyl] methyl}amino)phenyl]cyclopropanecarboxylic acid;

(-)-(cis)-2-[4-({[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Enantiomerically enriched-(trans)-ethyl-2-[2-chloro-4-({[3-(phenyloxy)phenyl]methyl}amino)phenyl]cyclopropanecarboxylate;

(+)-(Trans)-2-[2-chloro-4-({[3-(phenyloxy)phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

Enantiomerically enriched-(trans)-ethyl-2-[2,5-difluoro-4-({[3-(phenyloxy)phenyl]methyl}amino)phenyl]cyclopropanecarboxylate;

(+)-(trans)-2-[2,5-difluoro-4-({[3-(phenyloxy)phenyl]methyl}amino)phenyl]cyclopropanecarboxylic acid;

(+)-(trans)-2-{4-[(3,5-dichlorophenyl)oxy]phenyl}methyl}amino]phenyl}cyclopropanecarboxylic acid;

(+)-(trans)-2-(4-{[(3-{[3-(trifluoromethyl)phenyl]oxy}phenyl)methyl]amino}phenyl)cyclopropanecarboxylic acid;

(+)-(trans)-2-{4-[(3-{(4-methylphenyl)oxy]phenyl}methyl)amino]phenyl}cyclopropanecarboxylic acid;

Racemic-(trans)-2-{4-[(4-biphenylmethyl)amino]phenyl}cyclopropanecarboxamide;

Racemic-(trans)-2-[4-({[4-(2-pyridinyl)phenyl]methyl}amino)phenyl]cyclopropanecarboxamide;

Racemic-(trans)-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}-N-(4-pyridinylmethyl)cyclopropanecarboxamide;

Enantiomerically enriched (trans)-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}-N-(4-pyridinylmethyl)cyclopropanecarboxamide;

Enantiomerically enriched (trans)-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}-N-[(1S)-1-phenylethyl]cyclopropanecarboxamide;

Enantiomerically enriched (trans)-N-hydroxy-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;

Enantiomerically enriched (trans)-N-cyclobutyl-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino]phenyl}cyclopropanecarboxamide;

Racemic-(trans)-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}cyclopropanecarboxamide;
(+)-(trans)-*N*-(1-methylethyl)-2-{4-[(3-(phenyloxy)phenyl)methyl]amino}phenyl}cyclopropanecarboxamide;
Racemic-(trans)-*N*-isopropyl-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}cyclopropanecarboxamide;
Racemic-(trans)-*N,N*-dimethyl-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[(3-(phenyloxy)phenyl)methyl]amino}phenyl}-*N*-(4-pyridinylmethyl)cyclopropanecarboxamide;
Racemic-(trans)-*N*-(4-methoxybenzyl)-2-{4-[(3-phenoxybenzyl)amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[(3-phenoxybenzyl)amino]phenyl}-*N*-(4-(trifluoromethyl)benzyl)cyclopropanecarboxamide;
Racemic-(trans)-*N*-(2-morpholin-4-ylethyl)-2-{4-[(3-phenoxybenzyl)amino]phenyl}cyclopropanecarboxamide;
Racemic-(trans)-2-{4-[(3-phenoxybenzyl)amino]phenyl}-*N*-(2,2,2-trifluoroethyl)cyclopropanecarboxamide;
Racemic-(trans)-*N*-isopropyl-2-{4-[(4-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}cyclopropanecarboxamide;
Enantiomerically enriched *N*-isopropyl-2-{4-[(4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl)methyl]amino}phenyl}cyclopropanecarboxamide; and
Enantiomerically enriched *N*-(cyclopropylmethyl)-2-{4-[(3-phenoxybenzyl)amino]phenyl}cyclopropanecarboxamide,
including salts, solvates, and physiologically functional derivatives thereof.

26. Cancelled.

27. (Currently amended) A pharmaceutical composition comprising a compound according to claims 1 to 25, and a pharmaceutically acceptable carrier.

28. Cancelled.

29. Cancelled.

30. Cancelled.

31. Cancelled.


32. Cancelled.

33. (Currently amended) A method for the treatment or prophylaxis of conditions or disorders affected by GPR40 comprising the administration of a compound according to ~~any one of claims 1 to 25~~.

34. (Original) The method of claim 33 wherein the condition or disorder is one or more of diabetes, obesity, glucose intolerance, insulin resistance, metabolic syndrome X, hyperlipidemia, hypercholesterolemia, atherosclerosis, neurodegenerative diseases, and cerebrovascular conditions.

35. (Original) A process for the preparation of enantiomerically enriched-(trans)-ethyl-2-(4-amino-aryl)-cyclopropanecarboxylates comprising: mixing a nitrobenzene compound, a palladium compound, and a tin compound in an appropriate solvent with heating to prepare a styrene product; dissolving said styrene product in an appropriate solvent and adding a mixture of a copper (I) trifluoromethanesulfonate-toluene complex and (2R)-4-tert-Butyl-2-{1-[(4R)-4-tert-butyl-4,5-dihydro-1,3-oxazol-2-yl]-1-methylethyl}-4,5-dihydro-1,3-oxazole and ethyldiazoacetate; and purifying to give enantiomerically enriched cyclopropanecarboxylates.


36. (Currently amended) ~~An intermediate~~ compound of formula III d



formula III d.

37. (Currently amended)

~~An intermediate~~ compound of formula IIIe



formula IIIe.